how do the glp 1 drugs work agonists for diabetes GLP-1 and kidney: from physiology to pharmacology and outcomes in diabetes Primer: The Skinny on GLP-1s

Taken together, these pharmacokinetic findings indicate that the centrally mediated effects of GLP-1RAs are likely due to limited brain penetration or action at sites adjacent to the BBB, rather than widespread distribution throughout the central nervous system

2022;36 doi: 10.47176/mjiri.36.39

In diabetes, the drug is part of a tightly regulated metabolic control strategy

The SUMMIT trial below evaluated the effects of tirzepatide in obese patients with HFpEF

In this respect, GLP-1 receptor agonists represent disease-modifying agents with implications that extend well beyond the management of weight and glycaemia